Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
About Compugen (CGEN): Revolutionizing Cancer Immunotherapy with Computational Biology
Compugen Ltd. (NASDAQ: CGEN, TASE: CGEN) is a clinical-stage biotechnology company pioneering the use of computational discovery platforms to identify novel drug targets and develop next-generation cancer immunotherapies. Headquartered in Israel with offices in San Francisco, CA, Compugen leverages its proprietary Unigen™ platform, an AI/ML-powered predictive computational discovery engine, to decode complex cancer biology and uncover innovative therapeutic pathways. This unique approach positions Compugen at the forefront of the immuno-oncology field, where computational biology is transforming drug discovery and development.
Core Business Model and Revenue Streams
Compugen operates a hybrid business model that combines in-house drug development with strategic collaborations. Its primary revenue streams include milestone payments, royalties, and licensing agreements with leading pharmaceutical partners like Gilead Sciences and AstraZeneca. For example, its anti-IL-18 binding protein antibody, COM503 (licensed to Gilead), exemplifies the company's ability to advance novel therapies through early-stage development before transferring commercialization rights to partners. This model not only mitigates financial risk but also accelerates the path to market for its groundbreaking therapies.
Therapeutic Pipeline: Addressing Unmet Needs in Oncology
Compugen's therapeutic pipeline focuses on overcoming immune resistance mechanisms in cancer. Key assets include:
- COM701: A potential first-in-class anti-PVRIG antibody for solid tumors, showcasing durable responses in challenging cancer types.
- COM902: A potential best-in-class anti-TIGIT antibody, designed to enhance T-cell activation. This program is further validated through AstraZeneca's rilvegostomig, a PD-1/TIGIT bispecific antibody derived from COM902, currently in Phase 3 trials.
- COM503: A high-affinity anti-IL-18 binding protein antibody licensed to Gilead, aimed at unleashing the anti-tumor potential of IL-18 within the tumor microenvironment.
These programs are supported by Compugen's predictive discovery capabilities, which integrate multi-omics data, single-cell RNA sequencing, and spatial transcriptomics to identify novel therapeutic targets.
Unigen™ Platform: The Engine Behind Innovation
At the heart of Compugen's success is its Unigen™ platform, a flexible-loop computational system that combines advanced AI/ML algorithms with biological data to accelerate drug discovery. This platform has yielded multiple first- and best-in-class immuno-oncology targets, including PVRIG and TIGIT, and continues to fuel the company's pipeline and partnerships. By integrating patient-derived data and single-cell sequencing, Unigen enables a deeper understanding of tumor biology, paving the way for personalized cancer therapies.
Strategic Collaborations and Industry Validation
Compugen's partnerships with pharmaceutical giants like Gilead and AstraZeneca underscore the industry's recognition of its innovative capabilities. These collaborations not only provide financial stability through milestone payments and royalties but also validate the scientific rigor of its computational platform. For instance, AstraZeneca's advancement of rilvegostomig into multiple Phase 3 trials highlights the clinical potential of Compugen's discoveries.
Market Position and Competitive Advantage
Compugen stands out in the competitive biotech landscape due to its computational-first approach, which reduces the time and cost of drug discovery. Unlike traditional methods, its platform-driven strategy allows for the rapid identification of novel targets and mechanisms of action, providing a significant edge in the fast-evolving field of immuno-oncology.
Challenges and Future Outlook
While Compugen's innovative approach offers significant advantages, the company faces challenges typical of clinical-stage biotechs, including the inherent risks of drug development and dependence on external partnerships for commercialization. However, its robust pipeline, strategic collaborations, and financial runway into 2027 position it well for sustained growth and innovation.
Conclusion
Compugen Ltd. is redefining cancer immunotherapy through its computational discovery capabilities and innovative pipeline. With a strong focus on addressing unmet medical needs, the company is poised to make a lasting impact on the oncology landscape. Its unique blend of predictive science, clinical expertise, and strategic partnerships ensures a promising future in the fight against cancer.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company will engage in a fireside chat scheduled for March 11, 2025, at 8:00 AM ET in Miami Beach, Florida.
Investors and interested parties can access a live webcast of the presentation through the events page in the Investor Relations section of Compugen's website (www.cgen.com). A replay option will be made available after the live event concludes.
Compugen (NASDAQ: CGEN) has announced the enhancement of its AI/ML predictive computational discovery platform, Unigen™, through collaboration with Ultima Genomics' single cell sequencing technology. The partnership combines Compugen's platform with Ultima's UG 100™ sequencing platform to gain deeper insights into tumor biology and immune regulation.
Key findings presented at the AGBT 2025 General Meeting revealed high consistency in single-cell expression levels between Ultima's UG 100 and Illumina's Novaseq 6000 platforms. The UG 100 demonstrated superior capability in identifying 3' mRNA transcript endings, potentially advancing the understanding of gene structure in tumor biology.
The collaboration aims to leverage Ultima's technology for developing proprietary single cell atlases to accelerate new immunotherapy discoveries. The research findings contribute to Unigen's predictive models, with potential applications in developing new cancer immunotherapies.
Compugen (CGEN) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before U.S. markets open. The clinical-stage cancer immunotherapy company will host a conference call and webcast at 8:30 am ET, where management will review financial results and provide a corporate update.
Investors can access the conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A live webcast will be available through Compugen's website, with a replay accessible afterward.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual conference on February 11, 2025, at 8am ET.
Investors and interested parties can access a live webcast of the presentation through the Investor Relations section of Compugen's website at www.cgen.com. For those unable to attend the live session, a replay will be made available after the event.
AstraZeneca and Daiichi Sankyo have initiated the TROPION-Lung12 Phase 3 trial, dosing their first patient to evaluate DATROWAY® (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy versus standard of care. The trial targets patients with stage 1 adenocarcinoma non-small cell lung cancer (NSCLC) after complete surgical resection who are ctDNA-positive or have high-risk pathological features.
Currently, stage 1 NSCLC treatment involves tumor resection, but up to 40% of patients may experience disease recurrence. While observation typically follows resection, adjuvant chemotherapy and/or immunotherapy may be offered to high-risk stage 1b patients. The trial aims to explore DATROWAY's potential role in combination with immunotherapy as an adjuvant treatment to prevent disease recurrence.
Compugen (NASDAQ: CGEN) has announced the dosing of its first patient in a Phase 1 clinical trial for COM503, a potential first-in-class antibody against IL-18 binding protein licensed to Gilead Sciences. The multi-center trial will evaluate COM503's safety, tolerability, and pharmacokinetics both as a monotherapy and in combination with Gilead's anti-PD1, zimberelimab, in patients with advanced solid tumors.
The trial, initiated in Q4 2024, represents a new approach to cancer treatment through cytokine biology. Compugen's Unigen™ discovery engine identified high IL-18 expression in cancer patients' tumors, but found its anti-tumor activity is blocked by an endogenous IL-18-binding protein. COM503 works by blocking this protein, potentially enabling naturally occurring IL-18 to fight cancer within tumors, addressing limitations of systemic cytokine administration.
The first patient was dosed at the START Center for Cancer Research-Midwest in Grand Rapids, Michigan, with Compugen responsible for conducting the Phase 1 trial.
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduced Fc clinical-stage antibody, in combination with any anti-PD-1 and anti-PVRIG antibodies. The patent is set to expire no earlier than August 2037.
The company highlights that recent developments suggest potential advantages of anti-TIGITs without active Fc binder, like COM902. Their data indicates blocking TIGIT alone may be insufficient for optimal anti-tumor activity in certain cases, particularly in tumors non-responsive to PD-1 inhibition.
Compugen (NASDAQ: CGEN) reported Q3 2024 financial results and corporate updates. The company presented clinical data for COM701 at SITC 2024, showing durable responses in immunotherapy-resistant tumors. Plans include initiating an adaptive platform trial for COM701 in Q2 2025 for ovarian cancer patients. The company reported $17.1 million in revenues and a net profit of $1.3 million for Q3 2024. Cash position stands at $113.2 million, expected to fund operations into 2027. Partner AstraZeneca advanced rilvegostomig into additional Phase 3 trials, while COM503's Phase 1 trial is set to begin in Q4 2024.
Compugen (Nasdaq: CGEN) announced its participation in the Stifel 2024 Healthcare Conference in New York City. The company's management will engage in a fireside chat scheduled for Monday, November 18, 2024, at 8:35 am ET. The event will be accessible through a live webcast on the Investor Relations section of Compugen's website, with a replay available after the event. Compugen, operating as a clinical-stage cancer immunotherapy company, is known for its pioneering work in computational target discovery.
Compugen (CGEN) has announced promising data on the triple combination of COM701, COM902, and pembrolizumab in treating platinum-resistant ovarian cancer patients. The data will be presented at the SITC 2024 conference in Houston, Texas. The study showed a 17.4% confirmed objective response rate and a 43.5% disease control rate in 23 evaluable patients.
The treatment demonstrated a favorable safety profile with mostly Grade 2 or lower adverse events, and only one Grade 3 event reported. Dr. Oladapo Yeku from Harvard Medical School highlighted the treatment's durability and effectiveness in late-stage ovarian cancer patients. The company plans to advance COM701 to earlier stages of ovarian cancer therapy, particularly targeting patients who are ineligible for maintenance treatment.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen's core business focus?
How does Compugen generate revenue?
What is the Unigen™ platform?
What are Compugen's key therapeutic candidates?
Who are Compugen's major partners?
What differentiates Compugen from other biotech companies?
What is rilvegostomig, and how is it related to Compugen?
What are the risks associated with Compugen's business model?
What is the significance of the COM503 program?
What is Compugen's financial outlook?
